Agilent (A) Received its Third Buy in a Row

By Carrie Williams

After Deutsche Bank and Robert W. Baird gave Agilent (NYSE: A) a Buy rating last month, the company received another Buy, this time from Jefferies. Analyst Brandon Couillard reiterated a Buy rating on Agilent yesterday and set a price target of $90. The company’s shares closed yesterday at $77.89, close to its 52-week high of $78.80.

According to TipRanks.com, Couillard is a top 25 analyst with an average return of 27.9% and a 75.4% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Danaher Corp, and PerkinElmer.

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $84, a 7.8% upside from current levels. In a report issued on February 12, Deutsche Bank also maintained a Buy rating on the stock with a $85 price target.

See today’s analyst top recommended stocks >>

Agilent’s market cap is currently $24.77B and has a P/E ratio of 79.84. The company has a Price to Book ratio of 5.42.

Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates through the following segments: Life Sciences & applied markets; Diagnostics & Genomics; and Agilent CrossLab.